Somewhat Positive Media Coverage Somewhat Unlikely to Affect EXACT Sciences (EXAS) Share Price

News articles about EXACT Sciences (NASDAQ:EXAS) have trended somewhat positive this week, according to Accern. Accern identifies negative and positive press coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. EXACT Sciences earned a media sentiment score of 0.23 on Accern’s scale. Accern also gave media stories about the medical research company an impact score of 45.5664440037097 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

These are some of the news articles that may have impacted Accern Sentiment’s scoring:

EXACT Sciences (NASDAQ:EXAS) traded up $1.10 during trading on Thursday, reaching $55.06. 1,699,484 shares of the company were exchanged, compared to its average volume of 1,930,000. The company has a market cap of $6,590.00, a price-to-earnings ratio of -47.88 and a beta of 0.68. EXACT Sciences has a twelve month low of $16.95 and a twelve month high of $63.60. The company has a quick ratio of 9.98, a current ratio of 10.34 and a debt-to-equity ratio of 0.01.

EXACT Sciences (NASDAQ:EXAS) last issued its quarterly earnings results on Monday, October 30th. The medical research company reported ($0.23) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.30) by $0.07. The firm had revenue of $72.60 million for the quarter, compared to analyst estimates of $65.03 million. EXACT Sciences had a negative net margin of 60.71% and a negative return on equity of 30.32%. The business’s revenue for the quarter was up 158.4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.36) EPS. research analysts anticipate that EXACT Sciences will post -1.1 earnings per share for the current year.

A number of analysts recently weighed in on EXAS shares. William Blair reaffirmed a “buy” rating on shares of EXACT Sciences in a report on Wednesday. Bank of America set a $67.00 target price on shares of EXACT Sciences and gave the stock a “buy” rating in a report on Monday. BidaskClub raised shares of EXACT Sciences from a “hold” rating to a “buy” rating in a report on Thursday, December 21st. Leerink Swann reaffirmed an “outperform” rating and set a $67.00 target price (up previously from $63.00) on shares of EXACT Sciences in a report on Monday, November 13th. Finally, Robert W. Baird lowered shares of EXACT Sciences from an “outperform” rating to a “neutral” rating and set a $56.00 target price on the stock. in a report on Monday, November 13th. Eight analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $50.58.

In other news, SVP D Scott Coward sold 1,665 shares of the stock in a transaction on Wednesday, January 3rd. The shares were sold at an average price of $52.54, for a total value of $87,479.10. Following the transaction, the senior vice president now owns 37,558 shares of the company’s stock, valued at approximately $1,973,297.32. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider Graham Peter Lidgard sold 45,775 shares of the stock in a transaction on Wednesday, November 1st. The stock was sold at an average price of $53.60, for a total transaction of $2,453,540.00. Following the completion of the transaction, the insider now directly owns 272,819 shares in the company, valued at approximately $14,623,098.40. The disclosure for this sale can be found here. Insiders sold a total of 610,433 shares of company stock worth $34,341,306 in the last three months. Insiders own 4.00% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This piece was originally published by Community Financial News and is the property of of Community Financial News. If you are reading this piece on another publication, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The correct version of this piece can be viewed at

EXACT Sciences Company Profile

Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.

Insider Buying and Selling by Quarter for EXACT Sciences (NASDAQ:EXAS)

Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit